4D Molecular Therapeutics Inc. (FDMT) News
Filter FDMT News Items
FDMT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FDMT News Highlights
- FDMT's 30 day story count now stands at 10.
- Over the past 29 days, the trend for FDMT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about FDMT are GENE, LUNG and AGE.
Latest FDMT News From Around the Web
Below are the latest news stories about 4D MOLECULAR THERAPEUTICS INC that investors may wish to consider to help them evaluate FDMT as an investment opportunity.
4D Molecular Therapeutics Stock Is Trading Higher Today - Here's Why4D Molecular Therapeutics (NASDAQ: FDMT) announced interim data from the 4D-710 Phase 1/2 AEROW trial for cystic fibrosis lung disease. The aerosol delivery procedure for 4D-710 was well tolerated. One patient experienced mild dry throat and fatigue during aerosol delivery. Following aerosol administration, 4D-710 was well tolerated in all 3 participants (9-12 months follow-up) with no 4D-710-related adverse events, dose-limiting toxicities, or serious adverse events. Biomarker analyses demonstr |
4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual Meeting4D-710 Clinical Activity & Biomarker Summary for Cohort 1 (n=3) Phase 1 Dose Exploration Cohort 1 Interim Clinical Activity Data: Table 1 Reported data from cohort 1 (n=3, 1E15 vg dose) of cystic fibrosis modulator treatment ineligible/intolerant participants with 9-12 months follow-up Quality of life outcomes measured by Cystic Fibrosis Questionnaire-Revised respiratory symptom score (CFQ-R-R) meaningfully improved for all three participants Percent predicted forced expiratory volume in one sec |
4D Molecular Therapeutics to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today it will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference Fireside Chat Date:Friday, June 9, 2023Fireside Chat Time:10:00 a.m. ETLocation:New York, NYWebcast Link:Webcast Goldman Sachs Global He |
4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual MeetingInterim data to be presented in an oral presentation by Dr. Jennifer L. Taylor-Cousar, MD, MSCS at the 2023 ECFS Annual Meeting in Vienna, Austria on Thursday, June 8, 2023 at 5:00 p.m. CET (11:00 a.m. ET)Company to host live webcast on Wednesday, June 7, 2023 at 4:30 p.m. ET EMERYVILLE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic me |
Institutional investors have a lot riding on 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) with 44% ownershipKey Insights Significantly high institutional ownership implies 4D Molecular Therapeutics' stock price is sensitive to... |
Andreas Halvorsen's Firm Storms Deeper Into 4D Molecular TherapeuticsFormer tiger cub's firm boosts holding in clinical-stage gene therapy company |
Andreas Halvorsen's Firm Packs Further Into 4D Molecular TherapeuticsFormer tiger cub's firm boosts holding in clinical-stage gene therapy company |
4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual MeetingEMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced a presentation on 4D-710 for the treatment of cystic fibrosis lung disease at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting held in Los Angeles, California on May 16-20, 2023. The oral presentation will be given by Jennifer L. Taylor-Cousar, M.D., |
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of 0% and 79.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational HighlightsPresented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration (wet AMD) at the 2023 ARVO Annual MeetingOn track for completion of enrollment of the Phase 2 Dose Expansion Stage of the PRISM clinical trial in Q3Acquired all worldwide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc. and announced sCFH as payload for 4D-175 lead product candidate for geographic atrophy (GA)Multiple additional cli |